An increased risk of alopecia areata was significantly associated with atopy and allergies, especially hay fever, eczema, asthma, and allergies to pollen, dust, and cats, according to a study ...

Most people with alopecia areata are otherwise healthy, but unpredictable hair loss can be emotionally upsetting and take a toll on your self-esteem and confidence. Certain lifestyle changes and ...

Senna M, et al. Long-term efficacy of baricitinib in alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023 ...

New treatment for teens with alopecia. The FDA approved the once-daily pill called Litfulo, created by pharmaceutical giant Pfizer, for people 12 and up to treat severe alopecia areata, or at ...

3. Stress Management. Stress can trigger alopecia areata symptoms, leading to more hair loss. You can incorporate stress management techniques into your day to help reduce stress and improve symptoms.

Source Reference: Senna MM, et al "Long-term efficacy of baricitinib in alopecia areata: 104-weeks results from BRAVE-AA1 and BRAVE-AA2" AAD 2023. Share on Facebook. Opens in a new tab or window ...

The FDA has approved Litfulo, a once-daily oral treatment, for the treatment of severe alopecia in individuals aged 12 years and older, Pfizer announced in a press release. Litfulo (ritlecitinib ...

The investigational drug deuruxolitinib is effective for hair regrowth in patients with alopecia areata, ... Senna was a clinical investigator of BRAVE-AA1, as well as of THRIVE-AA2.

Senna MM, King B, Mesinkovska AN, Mostaghimi A, Hamilton C, Cassella J. Efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with moderate to severe alopecia areata: pooled ...

The Cardinals cheerleader shared her journey with alopecia with Dobbs. She was diagnosed in January 2023, and by May 2023, 85% of her hair had fallen out.

Up to 100% of ritlecitinib responders sustained hair regrowth and 30% of nonresponders achieved results at week 48 with continuous treatment, according to a post hoc study analysis.